Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury
- PMID: 24361371
- DOI: 10.1016/j.jconrel.2013.12.008
Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury
Abstract
The combinational therapy with S1Plyase siRNA (siS1PLyase) and recombinant high mobility group box-1 box A peptide (HMGB1A) may have a synergistic effect for the treatment of acute lung injury (ALI). For efficient delivery, the R3V6 peptides were used as a carrier. The ternary complex of siS1PLyase, HMGB1A, and R3V6 was produced by charge interaction. The siS1PLyase/HMGB1A/R3V6 ternary complex delivered siRNA into the LA-4 lung epithelial cells more efficiently than polyethylenimine (PEI) and Lipofectamine. Furthermore, the ternary complex was non-toxic. The siS1PLyase/HMGB1A/R3V6 complex reduced the levels of IL-6 and TNF-α more efficiently than HMGB1A only or siS1PLyase/R3V6 complex in the LPS activated macrophage cells. In vivo administration of the siS1PLyase/HMGB1A/R3V6 complex reduced the S1PLyase level efficiently in an LPS-induced ALI model. Furthermore, the complex reduced the inflammatory response and apoptosis in the ALI model. In conclusion, siS1PLyase and HMGB1A have a synergistic therapeutic effect for the treatment of ALI. Furthermore, R3V6 is an efficient carrier for combined delivery of siS1PLyase and HMGB1A.
Keywords: Acute lung injury; Combined delivery; High mobility group box-1 A peptide; Sphingosine-1-phosphate lyase; siRNA.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Delivery of the high-mobility group box 1 box A peptide using heparin in the acute lung injury animal models.J Control Release. 2016 Jul 28;234:33-40. doi: 10.1016/j.jconrel.2016.05.039. Epub 2016 May 16. J Control Release. 2016. PMID: 27196743
-
Combination of TAT-HMGB1A and R3V6 amphiphilic peptide for plasmid DNA delivery with anti-inflammatory effect.J Drug Target. 2014 Sep;22(8):739-47. doi: 10.3109/1061186X.2014.916711. Epub 2014 May 15. J Drug Target. 2014. PMID: 24830301
-
Lung epithelial binding peptide-linked high mobility group box-1 A box for lung epithelial cell-specific delivery of DNA.J Drug Target. 2011 Aug;19(7):589-96. doi: 10.3109/1061186X.2010.547584. Epub 2011 Feb 10. J Drug Target. 2011. PMID: 21309682
-
Improved islet transplantation outcome by the co-delivery of siRNAs for iNOS and 17β-estradiol using an R3V6 peptide carrier.Biomaterials. 2015 Jan;38:36-42. doi: 10.1016/j.biomaterials.2014.10.060. Epub 2014 Nov 12. Biomaterials. 2015. PMID: 25457981
-
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18. Eur J Pharm Biopharm. 2011. PMID: 21093588 Review.
Cited by
-
Nucleic acid-based nanotherapeutics for treating sepsis and associated organ injuries.Theranostics. 2024 Jul 16;14(11):4411-4437. doi: 10.7150/thno.98487. eCollection 2024. Theranostics. 2024. PMID: 39113804 Free PMC article. Review.
-
Macrophages: Their role, activation and polarization in pulmonary diseases.Immunobiology. 2018 Apr-May;223(4-5):383-396. doi: 10.1016/j.imbio.2017.11.001. Epub 2017 Nov 12. Immunobiology. 2018. PMID: 29146235 Free PMC article. Review.
-
Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems.Kona. 2017;34:44-69. doi: 10.14356/kona.2017005. Epub 2016 Apr 30. Kona. 2017. PMID: 28392618 Free PMC article.
-
Anti-Inflammatory Therapeutic Effect of Adiponectin Gene Delivery Using a Polymeric Carrier in an Acute Lung Injury Model.Pharm Res. 2017 Jul;34(7):1517-1526. doi: 10.1007/s11095-017-2175-6. Epub 2017 May 10. Pharm Res. 2017. PMID: 28493099
-
Pulmonary surfactant as a versatile biomaterial to fight COVID-19.J Control Release. 2022 Feb;342:170-188. doi: 10.1016/j.jconrel.2021.11.023. Epub 2021 Nov 20. J Control Release. 2022. PMID: 34813878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
